 | • レポートコード：MRC2203A606 • 出版社/出版日：Mordor Intelligence / 2022年1月 • レポート形態：英文、PDF、115ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医薬品 |
| Single User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Site Licence | ￥962,000 (USD6,500) | ▷ お問い合わせ |
| Corporate License | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の本調査資料では、世界の急性リンパ芽球性白血病（ALL）治療薬市場について調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、細胞別（B細胞ALL、T細胞ALL）分析、治療法別（化学療法、標的療法、放射線療法、幹細胞移植）分析、地域別（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米）分析、競争状況、市場機会・将来の傾向などの項目を掲載しています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の急性リンパ芽球性白血病（ALL）治療薬市場規模：細胞別（B細胞ALL、T細胞ALL） ・世界の急性リンパ芽球性白血病（ALL）治療薬市場規模：治療法別（化学療法、標的療法、放射線療法、幹細胞移植） ・世界の急性リンパ芽球性白血病（ALL）治療薬市場規模：地域別（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米） ・競争状況（Bristol Myer Squibb Company、Celegene Corporation、Eisai Co Ltd、...） ・市場機会・将来の傾向 |
One of the major factors responsible for the growth of this market includes the rising occurrence of acute lymphoblastic leukemia (ALL) globally. The number of new cases being recorded each year is around 1.7 per 100,000 men and women per year. It has been estimated by the American Cancer Institute that in 2019, there will be around 5,930 new cases of ALL i.e. 3,280 in males and 2,650 in females. In addition, by 2020, it has been estimated that the number of cases of ALL may range around 0.4 to 2 per 100,000 population in the Asia-Pacific and South American countries.
There is a rise in the number of cases primarily due to the adoption of western lifestyles, including dietary changes and sedentary lifestyles. Moreover, globally, the prevalence is expected to increase during the forecast period, which shall be the major factor for the growth of this market.
Key Market Trends
Chemotherapy is Expected to Dominate the Type of Therapy Segment
The American Cancer Association stated that chemotherapy is the main treatment for the people suffering from acute lymphoblastic leukemia (ALL), and it has three phases, such as remission, consolidation, and maintenance. Chemotherapy uses cytotoxic drugs for the destruction of cancer cells.
Amsacrine (NordMedica), cyclophosphamide (Baxter), and cytarabine (Pfizer) are some of the drugs that are used for chemotherapy in ALL. Global pharmaceutical players, such as Baxter International, and Pfizer, are providing these drugs. ALL is the most common cancer in children, adolescents, and young adults younger than 20 years, accounting for 19.8% of all cancer cases in this age group, as per a 2019 report by the Leukemia & Lymphoma Society. Hence, the market for chemotherapy is also expected to boost due to high prevalence of ALL, especially among children.
North America to Dominate the Market Over the Forecast Period
North America is expected to dominate this market, due to the rising number of cases of this disease in the region, owing to genetic factors, environmental factors, and radiation. Moreover, favorable government policies, well-established healthcare infrastructure, and the presence of multinational companies make this region dominant in this market.
Asia-Pacific is also expected to register a high CAGR during the forecast period, owing to several factors, such as high unmet clinical needs, huge patient pool, and the rising awareness about early diagnosis in emerging countries.
Competitive Landscape
The market for acute lymphoblastic leukemia is moderately competitive and consists of the big players as well as the mid-sized companies. Owing to the rising focus of most of the pharmaceutical companies on oncology, it is expected that few new small-sized companies will also penetrate the market in the near future.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rise in the Incidences of Acute Lymphoblastic Leukemia
4.2.2 Increasing Initiatives Taken by the Government and Private Organizations
4.3 Market Restraints
4.3.1 Stringent Regulatory Pathways
4.3.2 High Cost Asscoiated with the Treatment
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Type of Cell
5.1.1 B-cell ALL
5.1.2 T-cell ALL
5.1.3 Philadelphia Chromosome: Positive (Ph+) and Negative (Ph-) ALL
5.2 By Type of Therapy
5.2.1 Chemotherapy
5.2.1.1 Hyper – CVAD Regimen
5.2.1.2 CALGB 8811 Regimen
5.2.1.3 Linker Regimen
5.2.1.4 Nucleoside Inhibitors
5.2.1.5 Other Types of Therapies
5.2.2 Targeted Therapy
5.2.3 Radiation Therapy
5.2.4 Stem Cell Transplantation
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East & Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East & Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Bristol Myer Squibb Company
6.1.2 Celegene Corporation
6.1.3 Eisai Co Ltd
6.1.4 Erytech Pharma
6.1.5 F. Hoffmann-La Roche Ltd
6.1.6 Genmab A/S
6.1.7 GlaxoSmithKline PLC
6.1.8 Novartis AG
6.1.9 Pfizer Inc.
6.1.10 Sanofi SA
7 MARKET OPPORTUNITIES AND FUTURE TRENDS